Tachyplesin III peptide

Tachyplesin III peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-KWCFRVCYRGICYRKCR-NH2 (Disulfide Bonds Between Cys3-Cys16, Cys7-Cys12)

H-Lys-Trp-Cys-Phe-Arg-Val-Cys-Tyr-Arg-Gly-Ile-Cys-Tyr-Arg-Lys-Cys-Arg-NH2 (Disulfide Bonds Between Cys3-Cys16, Cys7-Cys12)

17

95.14%

C₉₉H₁₅₅N₃₃O₁₉S₄

2239.75

Synthetic

Powder

Tachyplesin III (KWCFRVCYRGICYRKCR-NH2), which is derived from horseshoe crabs and exhibits antimicrobial activity against P. aeruginosa. After implantation of the Tachyplesin III-coated stent, P. aeruginosa was injected onto the implant surface. The Tachyplesin-III-treated group showed a reduction in bacterial count compared to uncoated stents, and this effect was further enhanced by co-treatment with intraperitoneal injection of piperacillin-tazobactam (TZP)

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Minardi, D., Ghiselli, R., Cirioni, O., Giacometti, A., Kamysz, W., Orlando, F., Silvestri, C., Parri, G., Kamysz, E., Scalise, G., Saba, V., and Giovanni, M. (2007) The Antimicrobial Peptide Tachyplesin III Coated Alone and in Combination with Intraperitoneal Piperacillin- Tazobactam Prevents Ureteral Stent Pseudomonas Infection in a Rat Subcutaneous Pouch Model. Peptides 28, 2293-2298.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.